Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Impact of pharmacist intervention in patients with Alzheimer's disease

Full text
Author(s):
Marcela Forgerini [1] ; Rosa Camila Lucchetta [2] ; Fernanda Mariana Oliveira [3] ; Maria Teresa Herdeiro [4] ; Marisa Veiga Capela [5] ; Patrícia de Carvalho Mastroianni [6]
Total Authors: 6
Affiliation:
[1] São Paulo State University. School of Pharmaceutical Sciences. Department of Drugs and Medicines - Brasil
[2] Federal University of Parana - Brasil
[3] São Paulo State University. School of Pharmaceutical Sciences. Department of Drugs and Medicines - Brasil
[4] University of Aveiro. Department of Medical Sciences. Institute of Biomedicine - Portugal
[5] São Paulo State University. Department of Physics and Chemistry - Brasil
[6] São Paulo State University. School of Pharmaceutical Sciences. Department of Drugs and Medicines - Brasil
Total Affiliations: 6
Document type: Journal article
Source: Brazilian Journal of Pharmaceutical Sciences; v. 58, 2022-08-08.
Abstract

Abstract To assess the therapy relative to indication, effectiveness, safety and adherence in patients with Alzheimer’s disease (AD). An interventional, prospective, non-randomized study was conducted in a single secondary care center in Brazil. The pharmacist-led medication therapy management (MTM) was conducted to detect drug-related problems (DRPs) at baseline and after six months of intervention. The health status outcomes (i.e. cognitive screening tests; levels of glucose; total cholesterol; triglycerides; thyroid stimulating hormone; serum free thyroxine and blood pressure) were measured. 66 patients with AD were included, of whom 55 patients completed the follow-up of six months. 36 patients (36/55) were non-adherent to AD drug therapy. Out of detected 166 DRPs, 116 were solved. Four patients were withdrawn from the AD protocol due to resolution of prodromal symptoms. On the conclusion of the study, the MTM improved and controlled blood pressure, glucose, total cholesterol, triglycerides levels (p<0.05). The pharmacist-led MTM was effective in solving 69.8% of DRPs, improving and controlling the clinical parameters evaluated. (AU)

FAPESP's process: 14/00312-5 - Impact of pharmacotherapy management in patients with Alzheimer's Disease
Grantee:Fernanda Mariana de Oliveira
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 18/07501-9 - Genetic determinants of gastrointestinal bleeding associated with the use of ASA as an antiplalet agent: a case-control study
Grantee:Marcela Forgerini
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)